Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KATHRYN S MOFFETT

Allopathic & Osteopathic Physicians Pediatrics Pediatric Infectious Diseases

NPI
1023132750
CMS profile
273107
Location
MORGANTOWN, WV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$122.10

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $122.10 1

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Vertex Pharmaceuticals Incorporated $122.10 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KATHRYN S MOFFETT

NPI 1023132750 · CMS profile ID 273107

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Infectious Diseases

MORGANTOWN, WV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1023132750?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KATHRYN S MOFFETT, NPI 1023132750, CMS profile ID 273107. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1023132750?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). KATHRYN S MOFFETT, NPI 1023132750, CMS profile ID 273107. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1023132750?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
KATHRYN S MOFFETT, NPI 1023132750, CMS profile ID 273107, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1023132750?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $122.10 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Vertex Pharmaceuticals Incorporated $122.1011/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899691909 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,406.97 15
PY2020 $6,132.82 15
PY2021 $33.95 1
PY2022 $122.10 1
PY2025 $17.50 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $32,650.14 2
PY2024 Principal investigator $69,780.52 3
PY2023 Principal investigator $68,365.82 5
PY2022 Principal investigator $77,924.85 6
PY2021 Principal investigator $37,326.44 11
PY2020 Principal investigator $81,879.44 29
PY2019 Principal investigator $114,244.75 47

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

29 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Gilead Sciences, Inc. $745.00 12/23/2020 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY RESEARCH CORP
A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Infection Trials No dispute reported 06/30/2026 742085197
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $20,000.00 11/25/2020 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY CLINICAL TRIALS RESEARCH UNIT
An Observational Study to Evaluate the Real-world Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor on the Burden of Illness in Cystic Fibrosis Patients and Caregivers No dispute reported 06/30/2026 805411623
Principal investigator 1 Tetraphase Pharmaceuticals, Inc. $500.00 11/17/2020 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY HOSPITAL
A Safety and PK Study of IV Eravacycline No dispute reported 06/30/2026 748315949
Principal investigator 1 Merck Sharp & Dohme Corporation $20.26 10/08/2020 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY RESEARCH CORPORATION
A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection No dispute reported 06/30/2026 753359879
Principal investigator 1 Merck Sharp & Dohme Corporation $29.70 10/08/2020 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY RESEARCH CORPORATION
A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection No dispute reported 06/30/2026 753359881
Principal investigator 1 Merck Sharp & Dohme Corporation $29.70 10/08/2020 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY RESEARCH CORPORATION
A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection No dispute reported 06/30/2026 753359883
Principal investigator 1 Merck Sharp & Dohme Corporation $29.70 10/08/2020 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY RESEARCH CORPORATION
A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection No dispute reported 06/30/2026 753359885
Principal investigator 1 Merck Sharp & Dohme Corporation $8.40 10/08/2020 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY RESEARCH CORPORATION
A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection No dispute reported 06/30/2026 753359887
Principal investigator 1 Janssen Research & Development, LLC $2,150.00 10/05/2020 Non-covered Recipient Entity
STATE OF WEST VIRGINIA WEST VIRGINI A UNIVERSITY
A Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Relationships of Different Doses of JNJ-53718678 in Children 28 Days and 3 Years of Age With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus Infection No dispute reported 06/30/2026 719521981
Principal investigator 1 AbbVie Inc. $1,485.02 08/06/2020 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY RESEARCH
P12-792 No dispute reported 06/30/2026 721180119
Principal investigator 1 VIVUS, Inc. $499.22 08/06/2020 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY
Long-term Study in US Cystic Fibrosis No dispute reported 06/30/2026 729994397
Principal investigator 1 Merck Sharp & Dohme Corporation $8,585.10 06/12/2020 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY
A Phase 1, open-label, non-comparative, multicenter clinical trial to evaluate the safety, tolerability, and pharmacokinetics of ceftolozane,tazobactam MK-7625A in pediatric participants with nosocomial pneumonia No dispute reported 06/30/2026 740848219
Principal investigator 1 Merck Sharp & Dohme Corporation $2,750.00 05/04/2020 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY
A Phase 1, open-label, non-comparative, multicenter clinical trial to evaluate the safety, tolerability, and pharmacokinetics of ceftolozane,tazobactam MK-7625A in pediatric participants with nosocomial pneumonia No dispute reported 06/30/2026 740741063
Principal investigator 1 Melinta Therapeutics, LLC $583.00 03/27/2020 Non-covered Recipient Entity
Western Institutional Review Board
An Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of Oritavancin Single Dose Infusion in Pediatric Patients Less Than 18 Years of Age With Suspected or Confirmed Bacterial Infections (ORKIDS) No dispute reported 06/30/2026 752633193
Principal investigator 1 Merck Sharp & Dohme Corporation $99.14 03/26/2020 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY
A Phase 1, open-label, non-comparative, multicenter clinical trial to evaluate the safety, tolerability, and pharmacokinetics of ceftolozane,tazobactam MK-7625A in pediatric participants with nosocomial pneumonia No dispute reported 06/30/2026 740741107
Principal investigator 1 Vertex Pharmaceuticals Incorporated $5,600.00 03/16/2020 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY CLINICAL TRIALS RESEARCH UNIT
An Observational Study to Evaluate the Real-world Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor on the Burden of Illness in Cystic Fibrosis Patients and Caregivers No dispute reported 06/30/2026 739730655
Principal investigator 1 Merck Sharp & Dohme Corporation $4.95 03/12/2020 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY RESEARCH CORPORATION
A Phase 2,3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection No dispute reported 06/30/2026 753359877
Principal investigator 1 Merck Sharp & Dohme Corporation $134.27 02/25/2020 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY
A Phase 1, open-label, non-comparative, multicenter clinical trial to evaluate the safety, tolerability, and pharmacokinetics of ceftolozane,tazobactam MK-7625A in pediatric participants with nosocomial pneumonia No dispute reported 06/30/2026 740741105
Principal investigator 1 Tetraphase Pharmaceuticals, Inc. $851.76 02/20/2020 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY HOSPITAL
A Safety and PK Study of IV Eravacycline No dispute reported 06/30/2026 748315803
Principal investigator 1 SANOFI PASTEUR INC. $7,500.00 02/13/2020 Non-covered Recipient Entity
West Virginia University Board Of Governors On Behalf Of West
MET42 Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 744043857
Principal investigator 1 SANOFI PASTEUR INC. $3,000.00 02/13/2020 Non-covered Recipient Entity
West Virginia University Board Of Governors On Behalf Of West
MET42 Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 744043871
Principal investigator 1 Tetraphase Pharmaceuticals, Inc. $100.00 02/11/2020 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY HOSPITAL
A Safety and PK Study of IV Eravacycline No dispute reported 06/30/2026 748315801
Principal investigator 1 Tetraphase Pharmaceuticals, Inc. $171.36 01/28/2020 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY HOSPITAL
A Safety and PK Study of IV Eravacycline No dispute reported 06/30/2026 748315793
Principal investigator 1 AbbVie Inc. $309.21 01/23/2020 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY RESEARCH
P12-792 No dispute reported 06/30/2026 721146727
Principal investigator 1 Allergan, Inc. $657.89 01/23/2020 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY RESEARCH CORPORATION
LONG-TERM STUDY IN US CYSTIC FIBROSIS PATIENTS RECEIVING DIGESTIVE ENZYME SUPPLEMENTS TO ASSESS ANY NARROWING OF THE LARGE INTESTINES CAUSING ADVERSE INTESTINAL SYMPTOMS (FIBROSING COLONOPATHY) No dispute reported 06/30/2026 721250523
Principal investigator 1 VIVUS, Inc. $103.95 01/23/2020 Non-covered Recipient Entity
WEST VIRGINIA UNIV RESEARCH CORPORATION
Long-term Study in US Cystic Fibrosis No dispute reported 06/30/2026 729994395
Principal investigator 1 Janssen Research & Development, LLC $2,500.00 01/02/2020 Non-covered Recipient Entity
STATE OF WEST VIRGINIA WEST VIRGINI A UNIVERSITY
A Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Relationships of Different Doses of JNJ-53718678 in Children 28 Days and 3 Years of Age With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus Infection No dispute reported 06/30/2026 719521977
Principal investigator 1 Janssen Research & Development, LLC $1,250.00 01/02/2020 Non-covered Recipient Entity
STATE OF WEST VIRGINIA WEST VIRGINI A UNIVERSITY
A Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Relationships of Different Doses of JNJ-53718678 in Children 28 Days and 3 Years of Age With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus Infection No dispute reported 06/30/2026 719521979
Principal investigator 1 Vertex Pharmaceuticals Incorporated $22,181.81 01/01/2020 Non-covered Recipient Entity
WEST VIRGINIA UNIVERSITY RESEARCH CORPORATION
A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy No dispute reported 06/30/2026 739729975